Skip to main content
Insmed's lung infection drug gets FDA priority review status
5/17/2018

The FDA accepted under a priority review status Insmed's Alis, or amikacin liposome inhalation suspension, as a treatment for patients with nontuberculous mycobacterial lung disease caused by the Mycobacterium avium complex. The agency set a PDUFA date of Sept. 28.

Full Story: